Evidence map›Paper›PMID 33829329›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2021

Disability progression in multiple sclerosis is associated with plasma neuroactive steroid profile.

C Cheng, D Gomez, J A McCombe, P Smyth, F Giuliani, G Blevins, G B Baker, C Power

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Steroid Sulfation in Neurodegenerative Diseases.Frontiers in molecular biosciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

C Cheng *Department of Psychiatry, University of Alberta, Edmonton, AB, Canada.
D Gomez *Department of Psychiatry, University of Alberta, Edmonton, AB, Canada.
J A McCombeDepartment of Medicine (Neurology), HMRC 6-11, University of Alberta, Edmonton, AB, Canada.
P SmythDepartment of Medicine (Neurology), HMRC 6-11, University of Alberta, Edmonton, AB, Canada.
F GiulianiDepartment of Medicine (Neurology), HMRC 6-11, University of Alberta, Edmonton, AB, Canada.
G BlevinsDepartment of Medicine (Neurology), HMRC 6-11, University of Alberta, Edmonton, AB, Canada.
G B BakerDepartment of Psychiatry, University of Alberta, Edmonton, AB, Canada.
C PowerDepartment of Psychiatry, University of Alberta, Edmonton, AB, Canada. chris.power@ualberta.ca.ORCID http://orcid.org/0000-0002-5131-9711
University of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeuroactive steroids (NASs) exert multiple biological effects on development and inflammation. The effects of NASs on disease progression in multiple sclerosis (MS) are uncertain, prompting analyses of NAS profiles during the transition from clinically isolated syndrome (CIS) to relapsing-remitting (RR) MS.

methodsSubjects with CIS or RRMS and healthy controls (HCs) were recruited; demographic and clinical data as well as disability scores measured by the Expanded Disability Status Scale (EDSS) were recorded. Matched plasma NAS and amino acid (AA) concentrations were measured.

resultsHC (n = 17), CIS (n = 31), and RRMS (n = 33) groups showed similar ages and sex distribution although disability scores were higher in the RRMS group. The conversion rate of CIS to RRMS group was 51.6% (n = 16) during a mean follow-up period of 1.85 years. The RRMS group showed significantly higher mean allopregnanolone, aspartate, and taurine concentrations with lower epiallopregnanolone concentrations than CIS patients, and higher L-serine-O-phosphate and lower alanine, arginine, and glutamine concentrations than the HC group. Among CIS and RRMS groups, multivariate hierarchical regressions revealed that higher concentrations of plasma tetrahydrodeoxycorticosterone (THDOC) may predict disability worsening.

conclusionsRRMS and CIS patients exhibited differing concentrations of both NASs and AAs in plasma while both THDOC and pregnanolone might serve as biomarkers of disability worsening.

Indexed as

Demyelinating DiseasesMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingNeurosteroidsDisease ProgressionHumansMagnetic Resonance ImagingNeurosteroidsAmino acidsClinically isolated syndromeDisability progressionMultiple sclerosisNeuroactive steroids

Identifiers

PMID33829329
OpenAlexW3139637058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.